Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
Top Cited Papers
- 25 May 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 115 (11) , 1355-1363
Abstract
National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice assigns patients aged 1-21 years with refractory solid tumors, brain tumors, lymphomas, and histiocytic disorders to phase II trials of molecularly targeted therapies based on detection of predefined genetic alterations. Patients whose tumors harbored EZH2 mutations or loss of SMARCB1 or SMARCA4 by immunohistochemistry were treated with EZH2 inhibitor tazemetostat. Patients received tazemetostat for 28-day cycles until disease progression or intolerable toxicity (max 26 cycles). The primary endpoint was objective response rate; secondary endpoints included progression-free survival and tolerability of tazemetostat. Twenty patients (median age = 5 years) enrolled, all evaluable for response and toxicities. The most frequent diagnoses were atypical teratoid rhabdoid tumor (n = 8) and malignant rhabdoid tumor (n = 4). Actionable alterations consisted of SMARCB1 loss (n = 16), EZH2 mutation (n = 3), and SMARCA4 loss (n = 1). One objective response was observed in a patient with non-Langerhans cell histiocytosis with SMARCA4 loss (26 cycles, 1200 mg/m2/dose twice daily). Four patients with SMARCB1 loss had a best response of stable disease: epithelioid sarcoma (n = 2), atypical teratoid rhabdoid tumor (n = 1), and renal medullary carcinoma (n = 1). Six-month progression-free survival was 35% (95% confidence interval [CI] = 15.7% to 55.2%) and 6-month overall survival was 45% (95% CI = 23.1% to 64.7%). Treatment-related adverse events were consistent with prior tazemetostat reports. Although tazemetostat did not meet its primary efficacy endpoint in this population of refractory pediatric tumors (objective response rate = 5%, 90% CI = 1% to 20%), 25% of patients with multiple histologic diagnoses experienced prolonged stable disease of 6 months and over (range = 9-26 cycles), suggesting a potential effect of tazemetostat on disease stabilization.Keywords
Funding Information
- NCTN Operations Center (U10CA180886)
- COG Biospecimen Bank (U24CA196173)
- NCTN Statistics and Data Center (U10CA180899)
- St. Baldrick’s Foundation
- NIH
This publication has 27 references indexed in Scilit:
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin LymphomaMolecular Cancer Therapeutics, 2014
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2Proceedings of the National Academy of Sciences of the United States of America, 2013
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsNature Chemical Biology, 2012
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphomaNature, 2011
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomasProceedings of the National Academy of Sciences of the United States of America, 2010
- Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic TransformationCancer Cell, 2010
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center originNature Genetics, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behaviorLaboratory Investigation, 2008
- Dosage-dependent modifiers of polycomb and antennapedia mutations in Drosophila.Proceedings of the National Academy of Sciences, 1988